Article
Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells.
Leukemia & lymphoma - 1 Jan 2018
Cheng Zhiyong, Fu Jianzhu, Liu Guimin, Zhang Lijun, Xu Qian, Wang Su-Yun
Abstract excerpt
Angiogenesis and JAK2 V617F mutation are common in BCR-ABL1 negative myeloproliferative neoplasms (MPNs). Ruxolitinib, a JAK inhibitor, is an effective treatment for some MPNs. However, the relationship between angiogenesis and JAK2 V617F and the effects of ruxolitinib on angiogenesis are still unknown. Here, we observed the correlation of JAK2 V617F mutation burden with VEGF, HIF-1a and microvascular density...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.